Partnership Opportunities


Oncoceutics is actively exploring partnership opportunities in the following areas:
  • Lead drug candidate ONC201: Partnerships for late-stage clinical development and commercialization
  • Imipridone platform: Research partnerships including medicinal chemistry, biological profiling and lead optimization for molecules in the imipridone family


Oncoceutics collaborates with leading cancer centers around the world. These collaborations explore the unique mechanisms and therapeutic potential of imipridones, and their ability to selectively target G-protein coupled receptors (GPCRs) and ClpP.

Lead cancer centers are working with Oncoceutics to explore the efficacy of imipridones in clinical trials via a variety of grant-funded and collaborative mechanisms. Oncoceutics and MD Anderson Cancer Center have a strategic agreement that provides for a sharing of risk and potential commercialization of ONC201 and ONC212.